Machina Capital S.A.S. acquired a new position in Stryker Corporation (NYSE:SYK – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 9,770 shares of the medical technology company’s stock, valued at approximately $2,691,000.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Bahl & Gaynor LLC purchased a new position in Stryker in the third quarter valued at $40,390,000. AMG National Trust Bank boosted its stake in shares of Stryker by 2.7% during the 3rd quarter. AMG National Trust Bank now owns 15,572 shares of the medical technology company’s stock worth $4,288,000 after acquiring an additional 407 shares in the last quarter. Moneco Advisors LLC boosted its stake in shares of Stryker by 13.5% during the 3rd quarter. Moneco Advisors LLC now owns 2,353 shares of the medical technology company’s stock worth $648,000 after acquiring an additional 279 shares in the last quarter. Mesirow Financial Investment Management Inc. grew its position in shares of Stryker by 58.9% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 104,547 shares of the medical technology company’s stock valued at $28,791,000 after acquiring an additional 38,753 shares during the period. Finally, Lido Advisors LLC grew its position in shares of Stryker by 4.3% during the 3rd quarter. Lido Advisors LLC now owns 48,866 shares of the medical technology company’s stock valued at $13,457,000 after acquiring an additional 2,010 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.
Stryker Stock Down 1.7%
Shares of NYSE SYK opened at $318.67 on Thursday. The company’s 50-day simple moving average is $292.27 and its 200-day simple moving average is $323.05. Stryker Corporation has a 52-week low of $267.00 and a 52-week high of $389.33. The firm has a market cap of $121.31 billion, a price-to-earnings ratio of 33.94, a price-to-earnings-growth ratio of 2.23 and a beta of 0.78. The company has a quick ratio of 1.30, a current ratio of 2.18 and a debt-to-equity ratio of 0.60.
Stryker (NYSE:SYK – Get Free Report) last released its earnings results on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). Stryker had a return on equity of 23.74% and a net margin of 13.78%. The company had revenue of $6.52 billion for the quarter, compared to analysts’ expectations of $6.62 billion. During the same period in the prior year, the firm earned $3.19 EPS. The firm’s revenue for the quarter was up 7.6% on a year-over-year basis. Equities analysts predict that Stryker Corporation will post 14.85 EPS for the current fiscal year.
Analysts Set New Price Targets
SYK has been the subject of several recent analyst reports. UBS Group cut their price target on Stryker from $400.00 to $382.00 and set a “buy” rating for the company in a research note on Monday, August 3rd. Citizens Jmp lowered their price target on Stryker from $400.00 to $390.00 and set a “market outperform” rating on the stock in a research report on Friday, October 30th. Evercore raised their price objective on Stryker from $335.00 to $355.00 in a report on Wednesday, October 28th. Needham & Company LLC dropped their price objective on Stryker from $418.00 to $359.00 and set a “buy” rating on the stock in a report on Friday, October 30th. Finally, TD Cowen cut their price objective on Stryker from $298.00 to $290.00 and set a “hold” rating for the company in a research report on Friday, October 30th. Twenty-one equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and an average target price of $342.19.
Read Our Latest Stock Report on SYK
Insider Activity at Stryker
In other Stryker news, insider Dylan Crotty sold 441 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the transaction, the insider owned 6,102 shares of the company’s stock, valued at $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 550,000 shares of the stock in a transaction that occurred on Friday, November 6th. The shares were sold at an average price of $325.32, for a total value of $178,926,000.00. Following the transaction, the director directly owned 1,701,375 shares of the company’s stock, valued at $553,491,315. The trade was a 24.43% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 901,267 shares of company stock valued at $297,123,701. 4.60% of the stock is owned by corporate insiders.
Stryker Company Profile
Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.
Read More
- Five stocks we like better than Stryker
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
